Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Regorafenib hydrate in preparing drug for treating pulmonary fibrosis

A technology for pulmonary fibrosis and regorafenib, which is applied in the application field of regorafenib hydrate in the preparation of drugs for treating pulmonary fibrosis diseases, and achieves good application prospects, no adverse reactions, and effects of slowing pulmonary fibrosis.

Inactive Publication Date: 2019-05-31
NANKAI UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no report that regorafenib hydrate can slow down pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Regorafenib hydrate in preparing drug for treating pulmonary fibrosis
  • Application of Regorafenib hydrate in preparing drug for treating pulmonary fibrosis
  • Application of Regorafenib hydrate in preparing drug for treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0022] Example: Regorafenib hydrate slows down bleomycin-induced lung fibrosis in mice.

[0023] Animal model preparation: male C57BL / 6J, wild-type mice (8-10 weeks old), give mice anesthesia by intraperitoneal injection of 0.5ml / 100g (body weight) with mass volume solubility 10% chloral hydrate, and there is Intravenous injection of 2U / Kg bleomycin.

specific Embodiment approach

[0024] The specific implementation method is as follows: after the mouse is anesthetized, weigh and record, fix the mouse on the operating table, disinfect the neck with 70% alcohol, use a scalpel to make a vertical wound of about 1 cm in the neck of the mouse, and use micro tweezers to separate The tissue exposed the trachea, and the syringe was pierced into the trachea through the gap between the tracheal cartilage rings toward the heart, and then slowly injected with a volume of bleomycin saline solution corresponding to its body weight at a rate of 2 U / kg, and immediately turned the animal upright and left and right to make The liquid medicine is evenly distributed in the lungs.

[0025] The blank control group was injected with the same volume of normal saline (0.9% Nacl).

[0026] Group administration: Regorafenib hydrate treatment refers to giving mice 30 mg / kg regorafenib hydrate by intragastric administration every day on the 7th to 14th day of bleomycin treatment, wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a Regorafenib hydrate in preparing a drug for treating pulmonary fibrosis and further provides a drug composition. The drug composition comprises the Regorafenibhydrate, a pharmaceutically acceptable salt or a pharmaceutically acceptable ester or a pharmaceutically acceptable hydrate of the Regorafenib hydrate or a composition of the pharmaceutically acceptable salt, ester and hydrate and accessories. The Regorafenib hydrate has a good effect on the pulmonary fibrosis, causes no adverse reactions, is capable of reducing the pulmonary fibrosis induced by bleomycin in mice, and provides a good application prospect for treating, easing or improving the pulmonary fibrosis.

Description

technical field [0001] The invention relates to a new application of regorafenib hydrate, in particular to the application of regorafenib hydrate in the preparation of medicines for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is the end-stage clinical manifestation of many pulmonary interstitial diseases with different etiologies, characterized by persistent alveolar damage, fibroblast proliferation, and massive extracellular matrix (ECM) deposition. A disease that causes alveolar and interstitial inflammation and fibrosis to varying degrees, leading to structural destruction of the lung and respiratory failure, so it is also called interstitial lung disease (ILD) or diffuse parenchymal lung disease (diffuse parenchymal lung disease, DPLD). [0003] Idiopathic pulmonary fibrosis (IPF) belongs to the idiopathic interstitial pneumonia (IIP) group in the family of interstitial lung diseases (ILDs). IPF is the most common and severe chron...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61P11/00
Inventor 王文瑞刘钦佚张德强龙士达吴舒扬黄凯阮灏李霄鹤周红刚
Owner NANKAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com